Intravenous Ketamine for Treatment-Resistant Depression
Recruiting
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)